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Abstract
The incidence of obesity is growing worldwide. In the United States, it is now 
estimated that one in three adults is categorized as obese. Obesity is a risk factor for 
multiple forms of cancer, and obese individuals have a higher risk of death. This 
chapter will share insight into how obesity is associated with cancer development, 
progression, and drug resistance by looking at the interplay between adipocytes 
(fat cells) and cancer cells. In particular, we will focus on alterations that occur in 
an obese state and biological mechanisms such as inflammation, oxidative stress, 
and hormonal imbalances that contribute to increased cancer risk.
Keywords: adipocyte, adipokine, adiponectin, adipose, cancer, estrogen, HIF, 
hormone, hyperinsulinemia, hypoxia, IFNγ, inflammation, insulin, leptin, MAPK, 
obesity, resistance, T cell
1. Introduction
Obesity has reached epidemic levels in the United States, and it is a growing health 
concern worldwide. It is estimated that one in three adults in the US is obese, while 
another one in three is overweight [1]. Worldwide, obesity has close to tripled since 
1975. In 2016, 13% of adults were categorized as obese and 39% as overweight [2]. 
Obesity is a risk factor for multiple diseases, including heart disease, stroke, type 2 
diabetes, and cancer, and obese individuals have a higher risk of death [1–3]. In the US, 
quality-adjusted life years lost to obesity are now higher than those lost to smoking [4].
“Obesity” is most often defined by body mass index (BMI), a calculation based 
on a ratio of one’s height and weight (kg/m2). “Obese” refers to a BMI of 30 or more, 
while “overweight” is categorized as a BMI between 25–30 and “normal weight” is 
defined as a BMI of 18.5–25.
Cancer describes the uncontrolled growth of cells which can metastasize, or spread, 
to other parts of the body. It can occur in any tissue and can be caused by a variety of 
environmental and genetic factors. About 15–20% of all cancers are estimated to be 
caused by being obese or overweight [5, 6]. Obese patients diagnosed with many types 
of cancers tend to have a worse prognosis, increased risk of metastatic cancers, and a 
shorter remission period than normal weight individuals [4, 7]. However, some can-
cers are more strongly associated with obesity than others [4, 7], and the correlation is 
dependent mainly on tissue type and patient cohort [5]. Cancers that are most closely 
correlated with obesity include: kidney [8], endometrial [9], ovarian [8], liver [10], 
pancreatic [11], gastrointestinal [8], colorectal [12], prostate [13], and postmenopausal 
breast cancer [14]; and multiple myeloma [7, 8, 15, 16]. Postmenopausal women are an 
especially susceptible patient cohort, as half of all cancers in this group are caused by 
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obesity [5]. The most common cancers caused by obesity in post-menopausal women 
are breast, endometrial, and ovarian cancers (Figure 1).
Besides storing lipids, adipose tissue is increasingly being recognized as the larg-
est endocrine organ in the body. The adipose tissue itself is comprised of multiple 
cell types, including adipocytes, immune cells, and endothelial cells, among others 
[17]. Adipocytes themselves can secrete a variety of adipokines, hormones, and 
inflammatory factors [17]. As such, adipocytes are involved in signaling pathways 
with neighboring cells. Signaling mechanisms in the adipose tissue are altered by 
obesity and can contribute to cancer development, progression, and drug resis-
tance. Cancers that are in direct contact with adipocytes, such as breast cancer, 
and even cancers that are in close proximity to adipocytes, such as colon cancer 
and endometrial cancer, are most susceptible to increased aggression stimulated 
by adipocyte signaling [17]. This chapter will focus on a few of the mechanisms 
through which adipocytes affect the tumor microenvironment (TME), including 
insulin resistance and hyperinsulinemia, sex steroid hormone signaling, changes in 
the adipokine profile, and chronic inflammation and hypoxia.
2. Adipose tissue
Generally, adipose tissue is divided into two main groups: visceral adipose tissue 
(VAT), which surrounds internal organs, and subcutaneous adipose tissue (SAT), 
which is located just under the skin. These two types of adipose tissue show large 
differences in metabolic activity and influence on disease risk [18]. Generally, both 
SAT and VAT increase in volume in obesity. However, too much VAT is associated 
with more negative health effects than SAT.
Visceral obesity, rather than subcutaneous obesity, increases the risk of multiple 
diseases including cancer [18]. This phenomenon is manly a result of the differing 
physiological roles of VAT and SAT. VAT acts as an endocrine organ and can signal 
other parts of the body via adipokine and cytokine secretion [18]. It also contains 
more immune cells and is more highly vascularized than SAT [19]. VAT adipocytes 
are generally more metabolically active than SAT adipocytes [19], and as such, most 
of the changes that occur to adipose tissue during obesity occur in VAT rather than 
Figure 1. 
Obesity can increase the risk of many cancers, including: cervical, endometrial, uterine, breast, ovarian, 
thyroid, colorectal, renal, liver, pancreatic, gallbladder, gastric, and esophageal cancer; non-Hodgkin’s 
lymphoma; and multiple myeloma.
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in SAT [19]. Overall, VAT is a stronger predictor of mortality due to obesity than 
SAT [19], especially when the VAT surrounding abdominal organs is high [18].
SAT acts as more of a storage tissue than VAT, as SAT adipocytes absorb free fatty 
acids and store them as triglycerides [19]. Increased SAT is generally not strongly 
associated with obesity-related cancers [18], with the exception of abdominal 
SAT. Multiple studies have shown that increased abdominal SAT can promote 
cancer growth progression, sometimes independently of overall adiposity [15, 20]. 
SAT (excluding abdominal SAT) has actually shown a somewhat protective role in 
cancer. Patients with more SAT generally have increased survival rates after treat-
ment than those with less SAT [21].
This paper will focus on VAT, as this tissue type is most strongly correlated with 
cancer risk. Thus, references made to obesity and adipocytes throughout the rest of 
this paper refer to VAT.
3. Insulin resistance and hyperinsulinemia
Insulin is a hormone that is primarily responsible for stimulating glucose uptake 
and storage, but it is involved in multiple evolutionarily conserved pathways 
involving cell growth and proliferation [22, 23]. This pluripotency is not unusual. 
Signaling pathways related to nutrient availability and growth are closely related, 
as uptake of nutrients is essential for supporting growth on both a systemic and 
intracellular level in the body [24].
Obesity, which is characterized by an excess of nutrient availability, stimulates 
the body to increase insulin secretion and continually activate growth pathways. 
In this way, obesity can change the balance of inter- and intracellular signaling 
that controls cycle progression, growth, proliferation, and angiogenesis. Any of 
these effects in excess can contribute to neoplastic transformation, and since these 
pathways are highly conserved and interconnected, any alterations to one pathway 
risk overcompensation through another [24]. Thus, the increase in insulin secretion 
and growth activation caused by obesity can directly contribute to tumor develop-
ment and progression.
3.1 Insulin and insulin-like growth factors
Insulin is secreted by pancreatic beta cells when serum glucose levels are 
elevated. The insulin then enters the bloodstream and binds insulin receptors (IR) 
on the plasma membrane of target cells. IRs are a type of receptor tyrosine kinase 
(RTK). Thus, binding of the ligand causes autophosphorylation of the tyrosine 
residues on the cytoplasmic tails of IRs, activating signaling pathways related to cell 
growth, proliferation, and glucose metabolism [5, 24, 25] (Figure 2).
There are two isoforms of IRs that are created by alternative splicing of the 
insulin receptor (INSR) gene: IR-B and IR-A. IR-B is expressed at high levels in 
adipocytes, hepatocytes, and muscle cells, as it is the isoform that regulates glucose 
metabolism [26]. IR-A is usually expressed at low levels in most normal cells com-
pared to IR-B, but it is the isoform that is often over-expressed in cancer cells [26].
Insulin-like growth factors (IGFs) are endocrine hormones that are homologous 
to and have a similar mechanism of action as insulin [24, 27]. While insulin is 
primarily involved in glucose metabolism via IR/PI3K signaling, IGFs are directly 
responsible for stimulating cell growth and proliferation via IGF-1 receptor 
(IGF-1R)/mitogen activated protein kinase (MAPK) signaling (Figure 2). However, 
IR and IGF-1R signaling overlap to a large extent, and the exact conditions that 
determine their specificity are not well understood [23].
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There are two main types of IGFs, IGF-I and IGF-II, both of which are secreted 
by the liver in response to other growth hormones [5, 24]. Once in the tissue and 
bloodstream, IGFs are generally bound by IGF binding proteins (IGFBP), which 
both increase the half-life of IGFs [27] and prevent them from binding receptors 
[24, 27]. When serum glucose levels are elevated, IGFs dissociate from their bind-
ing proteins. IGF-1 can then bind IGF-1 receptor (IGF-1R), an RTK that is similar 
to IR [24], or, with lower affinity, IR-A [23]. Binding of IGF-1 to its receptor can 
activate MAPK signaling, inhibit p53, or stimulate hypoxia-inducible factor 1 alpha 
(HIF-1α) expression. The result of these pathways are cell growth and proliferation, 
evasion of apoptosis and metastasis, and angiogenesis, respectively [5]. IGF-II can 
bind both IGF-1R and IR-A with high affinity [5] and IR-B with low affinity [23].
Insulin and IGF signaling pathways are highly conserved, as they are essential 
for normal development [24, 27]. As such, disruptions in the balance of signaling 
through these pathways, such as changes in metabolism associated with obesity, can 
lead to cancer development and progression.
3.2 Insulin resistance, hyperinsulinemia, and cancer
In obese individuals, glucose is constantly produced in the liver in response to 
nutrient excess, and adipose tissue over-secretes insulin in response. However, 
chronic over-secretion of insulin can lead to insulin resistance. This condition 
occurs when the body only minimally responds to insulin and thus cannot metabo-
lize glucose. To compensate, beta cells secrete even more insulin, causing hyper-
insulinemia [5]. The high serum insulin levels caused by hyperinsulinemia have 
multiple physiological effects that can contribute to cancer progression.
High serum insulin levels can increase production of IGF-1, which, as discussed 
earlier, activates signaling pathways related to growth, proliferation, evasion of 
apoptosis and metastasis, and angiogenesis [5]. Cancer cells can then use these 
Figure 2. 
IR and IGF-1R can activate the same signaling pathways. In normal cells, stimulation of either receptor 
activates pathways related to cell growth and proliferation. IR is also responsible for regulating glucose 
metabolism, while IGF-1R activates signaling pathways related to evasion of apoptosis, metastasis, and 
angiogenesis. In obesity, this specificity is lost. Treatment with metformin activates AMPK signaling, which 
blocks many of the pathways activated by AKT and can decrease tumor growth and progression.
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pathways to meet their high metabolic demands [24]. Insulin can stimulate produc-
tion of growth hormone receptor (GHR), which, when bound to its ligand, stimu-
lates hepatic synthesis of IGF-1 [5]. Insulin can also decrease production of IGFBP-1 
and 2. This decrease leads to an increase in free IGF-1 in the serum [5].
Increased insulin and IGF-1 serum levels can cause overproduction and 
overstimulation of IR-A and IGF-1R, which is a phenomenon that is commonly 
observed in cancer cells [23]. The signaling pathways activated by IR and IGF-1R 
overlap, so overstimulation of both receptors leads to amplification of shared path-
ways such as mTOR and MAPK. As a result, excessive cell growth and proliferation 
can be stimulated [23]. The specific functions of insulin, IGFs, IR, and IGF-1R also 
often become convoluted in the context of cancer. In normal cells, IR is mainly 
responsible for controlling metabolism, while IGF-1R is more involved in regulating 
cell growth [23]. However, because IR and IGF-1R are highly homologous, a hybrid 
of the two receptors can form when they are both overexpressed. The hybrid has a 
higher affinity for IGF-1 than for insulin, which amplifies IGF signaling and thus 
contributes to cell growth, proliferation, and evasion of apoptosis. This hybrid can 
be expressed in normal cells, but it tends to be expressed more highly in cancer 
cells, especially of the breast and thyroid [5].
Some cancer treatments target IGF-1R, as this receptor is more historically 
known for its role in regulating cell growth. However, while preclinical studies tar-
geting this receptor were promising, clinical studies were widely unsuccessful, and 
many were terminated [23, 28]. Moreover, sensitivity to IGF-1R inhibition varies 
widely among tumors even though most have an overexpression of IGF-1R [23, 28, 
29]. Current studies are focusing on finding biomarkers that can predict sensitivity 
to IGF-1R inhibition [28]. Other studies aim to determine whether combination 
therapy might make IGF-1R inhibition more viable, such as IGF-1R inhibitors given 
with mTOR or IR inhibitors [28]. Since the functions of IGF-1R and IR overlap in 
the context of cancer, signaling through IR may be a mechanism of resistance to 
IGF-1R inhibitors. Some studies are researching whether targeting both IGF-1R and 
IR can prevent resistance from developing to IGF-1R inhibitors [23].
Other studies aim to determine whether common drugs used to treat diabetes, 
such as metformin, can have anti-cancer effects. So far, these studies have shown 
promising results. Metformin is used to decrease serum levels of insulin and hepatic 
glucose production in diabetic patients. However, metformin has been found to 
also increase AMPK production via inhibition of mitochondrial complex I. AMPK 
can then increase in insulin sensitivity and inhibit the mTOR/AKT pathway, which 
decreases glycolysis and lipid synthesis [30] (Figure 2). Both animal and clinical 
studies thus far have shown that metformin can decrease the risk of tumor develop-
ment and progression, though the exact mechanisms of action of the drug have yet 
to be elucidated [23]. The main side effect of the drug is gastrointestinal distur-
bance, which occurs in about 30% of patients [30].
In summary, hyperinsulinemia is a common condition in obesity that is charac-
terized by over-secretion of insulin and IGF-1. Both of these factors can contribute 
to overexpression of IR, IGF-1R, and the IR-A/IGF-1R hybrid, which can dysregu-
late growth and metabolism and have tumor-promoting effects.
4. Sex steroid hormones
It is already well-established that obesity can directly increase the concentration of 
circulating sex steroid hormones (SSH), especially estrogen. As such, obesity is a known 
risk factor for cancers that can be caused in part by increased levels of these hormones, 
such as breast, endometrial, uterine, ovarian, and prostate cancers [5, 6, 24].
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Estrogen is formed from the aromatization of androgens such as testosterone 
and androstenedione [24]. In premenopausal women, this aromatization takes 
place mainly in the ovaries [24], but it shifts to the adipose tissue and epidermis in 
postmenopausal women [17]. Estrogen production occurs primarily in the testes of 
men [31]. Once in circulation, estrogen can have multiple physiological effects.
Estrogen can bind ERs on cells to stimulate cell division [4], cell cycle progres-
sion [32], and increase proliferation and angiogenesis [24]. ER activation is a 
major contributor to cancer progression in ER+ breast cancers. ER+ breast cancers 
account for approximately 70% of human breast cancers overall [33], and obesity is 
known to increase the risk of these cancers in postmenopausal women [34]. In these 
cancers, overactive ER signaling can cause DNA damage by dysregulating genes that 
control cell cycle, such as Cyclin D1. Overactive ER signaling can also increase the 
formation of R-loops in genes that are activated by estrogen. R-loops are formed 
when newly-synthesized RNA binds its DNA template, and they can regulate 
certain aspects of transcription. However, in the context of ER overstimulation, an 
excess of R-loops can lead to double-stranded breaks in genes activated by estrogen, 
contributing to genome instability and dysregulation of cell growth and prolifera-
tion [32, 35]. Hormone therapy is often given post-surgery in ER+ breast cancers, 
which has been shown to improve survival and decrease the risk of relapse [33], 
illustrating the large extent to which ER signaling contributes to cancer progression.
The increased levels of estrogen caused by obesity can also increase IR-A expres-
sion and amplify IGF signaling in breast cancer. These factors can contribute to 
IGF-1R inhibitor resistance and inhibition of apoptosis, respectively, as discussed 
in the previous section [4, 5]. In addition, estrogen can act as a mitogen, activating 
MAPK pathways and RTKs that, like ER, lead to cell cycle progression, prolifera-
tion, and survival [5].
There are a few mechanisms that control the increase in circulating SSH caused 
by obesity. Adipose tissue can produce aromatase, and increased adiposity is 
correlated with an increased production of the enzyme. Aromatase stimulates the 
conversion of androgens to estrogens in both men and postmenopausal women. In 
excess, the enzyme can increase circulating concentrations of the estrogen estra-
diol, which can cause DNA damage as discussed [4]. This signaling mechanism is a 
likely explanation for why breast cancer risk increases with BMI in postmenopausal 
women that do not receive hormone replacement therapy [24]. Adipose tissue can 
also decrease production of globulins, which would otherwise bind and inhibit the 
activity of hormones such as estradiol [24], contributing to DNA damage.
Severe obesity can also modulate other molecules that can contribute to cancer risk 
and progression. The concentration of circulating glucocorticoids, hormones that act 
to negatively regulate cell cycle and decrease inflammation, can be downregulated 
[24]. Severe obesity can also stimulate an increase in serum concentrations of IGF-1 
and the pro-inflammatory cytokine IL-6. Both of these molecules can activate the 
androgen receptor and contribute to survival and proliferation in prostate cancer [24].
5. Adipokines
Adipokines are cytokines that are secreted by adipose tissue. These adipokines 
can play important roles in metabolism, endocrine activities, satiety, and inflam-
mation [5, 17, 24]. However, adipokines can also both contribute to and suppress 
tumorigenesis. Obesity is generally correlated with a decrease in tumor-suppressing 
and an increase in tumor-promoting adipokines. There are multiple types of adipo-
kines, but the most well-researched and abundant adipokines in the human body 
are leptin and adiponectin [5].
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5.1 Leptin
Leptin is the most well-known adipokine, and its main function is to suppress 
appetite [24]. It is secreted by adipose tissue in response to nutrient availability, and 
it binds leptin receptors on cells such as neurons, skeletal muscle cells, adipocytes, 
and epithelial cells [26]. This binding signals a decrease in appetite and creates a 
negative feedback loop between adipose tissue and the central nervous system [24].
Leptin production increases proportionally with body fat. However, leptin 
resistance often develops in the context of obesity. This resistance occurs because 
the adipose tissue in obese patients produces excessive amounts of leptin, which 
overstimulates leptin receptors. The receptors then become less sensitive to the 
adipokine, and in response, the adipose tissue secretes even more leptin [26, 36]. As 
a result, obese patients often experience a dysregulation in appetite where they do 
not feel satiated even when their body has taken in all necessary nutrients because 
their bodies do not respond to leptin.
Leptin has other important physiological functions besides appetite suppression. 
When bound to their ligand, leptin receptors can activate the PI3K, MAPK, and 
JAK/STAT signaling pathways. All of these pathways lead to either inflammation, 
cell growth and proliferation, angiogenesis, or prevention of apoptosis [5, 24]. Since 
leptin is often over-secreted in obesity, this adipokine is known to contribute to the 
systemic inflammation observed in many obese patients [17, 24, 26], which will be 
discussed in later sections of this chapter.
Leptin is also a likely link between obesity and cancer. Most studies researching 
leptin and cancer have been done in a breast cancer model. These studies have found 
that leptin increases aromatase expression, which upregulates estrogen production 
and ER signaling [5]. As discussed previously, ER signaling stimulates cell division, 
proliferation, and angiogenesis, and it prevents apoptosis [4, 24], all of which can 
contribute to tumorigenesis and cancer progression. Other studies have found that 
leptin may activate proliferation and survival of cancer cells in in vitro models of 
prostate, endometrium, and colon cancer [24].
5.2 Adiponectin
Adiponectin is the most abundant cytokine in the body, and it is the main hor-
mone produced by adipose tissue [7]. The major roles of adiponectin are to increase 
sensitivity to insulin [7] and increase energy expenditure [26]. By increasing insulin 
sensitivity, adiponectin can help prevent the development of insulin resistance and 
thus can help control glucose metabolism and growth [37]. Adiponectin can also 
inhibit angiogenesis and migration [37], stimulate apoptosis [24], and downregu-
late vascular endothelial adhesion molecules and decrease inflammation [37].
Adiponectin has a protective role in carcinogenesis [37], but serum levels of adipo-
nectin tend to decrease with increased BMI and visceral adiposity [26]. Adiponectin 
activates the AMPK pathway, which can inhibit mTOR and cause cell cycle arrest 
[37]. It also inactivates MAPK1/3 and ERK1/2 and can stimulate apoptosis by induc-
ing expression of p53 and Bax and decreasing expression of Bcl-2 [5]. However, 
estrogen and insulin both can suppress adiponectin secretion [5]. Thus, there is a 
complex balance of sex hormones, insulin, and adipokines that contribute to both 
obesity and cancer.
Current studies have shown the beneficial effects of adiponectin in cancer. 
Breast cancer risk is lower when serum levels of adiponectin are elevated in both 
pre and postmenopausal women [5]. Similarly, increased levels of adiponectin are 
associated with decreased risk of endometrial, colon, and prostate cancers [4]. 
Adiponectin has also been shown to inhibit growth in in vivo models of all of these 
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cancers [24]. Lower levels of adiponectin in men are correlated with a higher risk 
of colon cancer [5], and adiponectin has been shown to suppress the formation 
of colon polyps in mouse models of colon cancer [26]. In general, increased levels of 
adiponectin are correlated with a decrease in both the occurrence and severity of 
multiple cancers [5].
Other adipokines besides leptin and adiponectin exist. Resistin may be involved 
in promoting inflammation and angiogenesis, which can contribute to tumori-
genesis [4]. Plasminogen activator inhibitor type 1 (PAI-1) is generally used as 
an indicator of poor prognosis in breast cancer, especially in obese women [5]. 
High levels of PAI-1 often indicate low peroxisome proliferator-activated receptor 
gamma (PPARγ) function, which is a receptor that induces apoptosis and decreases 
proliferation. However, PPARγ expression is often downregulated in obesity. PAI-1 
can also inhibit apoptosis and induce inflammation, neutrophil recruitment, 
proliferation of smooth muscle cells, cell adhesion, and migration, all of which can 
contribute to tumorigenesis [5]. Growth-regulated oncogene alpha (GRO-α), tissue 
inhibitor of metalloproteinases 1 (TIMP-1), and thrombopoietin (TPO) are adipo-
kines that tend to be over-secreted in obesity and are believed to promote carcino-
genesis. GRO-α can promote inflammation and tumorigenesis; GRO-α and TIMP-1 
can promote cell proliferation, angiogenesis, and prevent apoptosis; and TPO can 
stimulate cell proliferation and differentiation of megakaryocytes [5].
6. Inflammation and hypoxia
The chronic nutrient overload that is characteristic of obesity contributes to 
inflammation and hypoxia both in adipose tissue and systemically. These effects can 
impact the tumor microenvironment (TME) to promote tumorigenesis and cancer 
progression through a variety of mechanisms.
In general, chronic nutrient overload leads to chronic inflammation of the 
adipose tissue, which is characterized by a sustained increase in inflammatory 
cytokines and infiltration of macrophages. Levels of adiponectin decrease, while 
leptin levels increase [26]. The inflammation can also induce hypoxia in the tissue, 
which can in turn induce more inflammation. Hypoxia is a state of low oxygen. One 
of the hallmarks of hypoxia is an increase in production of reactive oxygen species 
(ROS), which can mutate the DNA of nearby cells. These mutations can give cells a 
potentially cancerous phenotype. In these ways, chronic inflammation and hypoxia 
can contribute to tumorigenesis and cancer progression [17].
The TME describes the cellular environment that surrounds and feeds a tumor. 
Once a tumor is established, cells in the TME begin to behave in ways that promote 
the growth of the cancer. Normal mechanisms for blocking inflammation and 
encouraging immune surveillance are lost, and metabolic signaling is altered in 
order to promote the increased energy demand of rapidly-dividing cancer cells. This 
section will briefly outline the role of obesity-induced inflammation and hypoxia in 
carcinogenesis and in the TME overall.
6.1 The role of leptin in inflammation and hypoxia
The most notable effect of chronic inflammation in adipose tissue is an over-
secretion of leptin, an adipokine that was discussed previously in this chapter. 
Leptin can in turn induce more inflammation and hypoxia.
Leptin can stimulate cells in the TME to increase transcription of signaling 
molecules such as nitric oxide (NO) and cyclooxygenase-2 (COX-2) [17]. NO is 
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synthesized by nitric oxide synthases (NOS). The main role of NO is to respond to 
infection by causing inflammation and tissue damage. In excess, NO destroys enough 
tissue to induce a state of hypoxia, which is most often the case in the TME and in 
obesity. This tissue destruction stimulates more inflammation as a result of innate 
immune cell activation, further exacerbating the cycle. COX-2 upregulates produc-
tion of prostaglandins, which are precursors for inflammation, proliferation, and 
survival. It is downstream of NF-kB, which can be activated by the proinflammatory 
cytokine IL-1β. Overexpression of COX-2 has been observed in cancers including 
those of the prostate, colon, breast, lung, cervix, pancreas, skin, intestine, and 
stomach [38], and increased IL-1β expression in tumor cells is correlated with poor 
prognosis [17].
Leptin can also stimulate innate immune cells in the TME to secrete proinflam-
matory cytokines including IL-1, IL-6, TNFα, and IFNγ. IL-1 and IL-6 are used 
as markers for poor prognosis in many obesity-related cancers. IL-1 can activate 
NF-kB signaling to stimulate cytokine production and cell survival. IL-1 signaling 
through NF-kB also upregulates expression of hypoxia inducible factor 1 (HIF-1) in 
the context of obesity-induced inflammation, which induces hypoxia in the adipose 
tissue and supports angiogenesis, inflammation, and increased energy metabolism 
[26]. HIF-1 is correlated with increased metastatic spread and poor prognosis of 
cancer [5].
IL-6 expression is known to be elevated in obese patients [26]. It induces 
hypoxia in the adipose tissue, and it also stimulates angiogenesis, proliferation, 
and survival via the JAK/STAT signaling pathway [17]. Like IL-6, TNFα is com-
monly over-expressed in obese patients. However, TNFα is involved in all stages 
of tumorigenesis including cell proliferation, transformation, angiogenesis, 
invasion, and metastasis of cancer cells. TNFα may also stimulate an increase 
in ROS, which, as discussed, can cause potentially carcinogenic mutations in 
nearby cells [26].
The role of IFNγ is closely intertwined with T cell signaling in the adipose tissue. 
IFNγ stimulates naïve CD4+ T cells to differentiate into the type 1 subset (Th1), and 
it blocks differentiation into other subsets such as type 2 and type 17 helper T cells 
(Th2 and Th17, respectively). Th1 cells are effector T cells that stimulate macro-
phages to phagocytose foreign microbes in the body, and they both secrete and are 
stimulated by IFNγ [39]. Thus, a positive feedback loop occurs in obesity where 
over-secretion of leptin promotes IFNγ secretion, which stimulates Th1 differentia-
tion, which increases IFNγ secretion. IFNγ can then induce polarization of adipose 
tissue macrophages (ATMs) to the classical, or M1, phenotype. ATMs are innate 
immune cells that reside in the adipose tissue, and they are mainly responsible for 
clearing dead cells and debris [40]. Under normal conditions, the M1 phenotype 
generally induces an anti-microbial response [41]. It predominates in obese patients, 
and when activated, M1 ATMs secrete proinflammatory cytokines such as TNFα 
and IL-6. These cytokines can increase NO concentration in the adipose tissue and  
contribute to adipose tissue hypoxia. The overall result of M1 ATMs in obese 
patients is insulin resistance, inflammation, and hypoxia-induced tissue damage [26] 
(Figure 3).
The alternative, or M2, phenotype of ATMs generally induces immune toler-
ance and tissue remodeling under normal conditions [41]. It predominates in lean 
patients. These ATMs repair damaged tissue, prevent inflammation from starting, 
and inhibit insulin resistance. M2 ATMs are activated by anti-inflammatory cyto-
kines secreted by CD4+ type 2 helper T cells (Th2), which include IL-4, IL-10, and 
IL-13 [26] (Figure 3). Since M2 polarization is blocked by IFNγ, levels of M2 ATMs 
tend to be reduced in obese patients [17].
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6.2 The role of adipocytes in the tumor microenvironment (TME)
Cells and signaling pathways in the TME are altered by the tumor itself in order 
to promote cancer growth. Generally, the TME is characterized by an increase in 
inflammation and a decrease in immune surveillance. Adipocytes play a central 
role in these processes as they are on the interface of cell metabolism and the body’s 
immune response to the tumor. However, the role of adipocytes in the TME is still 
poorly understood as adipocytes were only recently recognized to have functions 
besides energy storage.
In direct contrast to the macrophage profile seen in obese patients, M2 macro-
phages in the TME exist in much higher numbers than their M1 counterparts. Tumor 
associated adipocytes (TAA), which are adipocytes that are in close proximity to 
and signal tumor cells, can induce M2 polarization [41]. The macrophages can also 
be repolarized, or the tumor can recruit M2 macrophages. In the TME, M2 macro-
phages promote tumor progression via angiogenesis, tissue repair, and secretion of 
anti-inflammatory cytokines. These cytokines can induce differentiation of T cells 
into regulatory T cells (Tregs), which prevent the host from mounting an immune 
response to the tumor. M1 macrophages inhibit tumorigenesis as they can recognize 
tumor cells as they would a foreign microbe. The M1 macrophages can then phago-
cytose the tumor cells or release toxins to destroy them. Thus, while M1 macrophages 
predominate in the adipose tissue of obese patients, the TME induces an increase 
in M2 polarization. In this way, the ATM profile in obesity may contribute to the 
inflammation needed to promote the early stages of tumor formation. In later stages, 
the TME flips the M1:M2 ratio in order to suppress the host’s immune response [41].
One of the characteristics of obesity is increased adipocyte death. If this increase 
in adipocyte cell death occurs in close proximity to a tumor, it can help fuel the 
Figure 3. 
Chronic nutrient overload, which is characteristic of obesity, can lead to chronic inflammation in the adipose 
tissue. This inflammation upregulates leptin secretion by adipocytes, which stimulates insulin resistance and 
IFNγ secretion by innate immune cells. IFNγ blocks differentiation of CD4+ T cells into the Th2 subtype, 
which would otherwise secrete anti-inflammatory cytokines, induce M2 polarization of ATMs, and block 
chronic inflammation. Instead, IFNγ stimulates differentiation of CD4+ T cells into the Th1 subtype, which 
secretes more IFNγ and induces M1 polarization of ATMs. These ATMs secrete more TNFα and IL-6, which 
contributes to adipose tissue hypoxia, chronic inflammation, and insulin resistance.
11
Obesity as a Promoter of Cancer Development and Progression
DOI: http://dx.doi.org/10.5772/intechopen.80516
growing cancer. The presence of dying adipocytes recruits M1 macrophages, which 
form crown-like structures (CLSs) around the cells to eliminate them [41]. The 
CLSs cause a release of DNA from the dying adipocytes into the tissue, which is 
recognized by toll-like receptor 9 (TLR-9) on macrophages. The macrophages 
mount a response, recruiting more monocytes to the site of the CLS and inducing 
more inflammation. The action of CLSs on adipocytes also causes a release of free 
fatty acids (FFA) into the tissue, which the tumor cells can use for fuel [41].
The “Warburg Effect” describes the change in metabolism from oxidative 
phosphorylation (OXPHOS) to glycolysis that cancer cells exhibit, and this change 
may explain some of the immunosuppressive effects of the TME. It is known that 
the TME has only a small number of effector T cells, which would otherwise detect 
and eliminate cancer cells. Most cells in the body use OXPHOS for ATP production, 
but activated CD8+ T cells tend to use glycolysis. Cancer cells also use glycolysis to 
produce ATP. As a result, cancer cells and effector T cells in the TME compete for 
the same nutrients. The cancer cells ultimately win, preventing the T cells from 
meeting their metabolic demands and halting their proliferation near the tumor 
[42]. Many oncogenes involve activation of glycolytic pathways, while many 
tumor suppressor genes induce OXPHOS. CD4+ T cells tend to be less affected by 
the Warburg Effect, however, as they can utilize both glycolysis and OXPHOS to 
produce ATP. Unstimulated T cells, which do not rapidly divide, use OXPHOS [42].
There are also other mechanisms that contribute to immune suppression in the 
TME. Tumor cells can stimulate macrophages to produce arginase 1 and the anti-
inflammatory cytokines IL-4 and TGFβ. All three factors recruit monocytes to the 
tumor microenvironment, which in turn recruit tumor-associated macrophages 
(TAMs). TAMs have multiple effects. They secrete vascular endothelial growth 
factor (VEGF) and fibroblast growth factor (FGF), which induce angiogenesis and 
metastasis, respectively. TAMs also block activation of most CD8+ T cells and some 
CD4+ T cells, which decreases immune surveillance similarly to the Warburg Effect. 
At the same time, TAMs recruit Tregs to the TME and secrete TGFβ and IL-10, 
which induce Treg differentiation. The TGFβ can also recruit more monocytes, 
beginning the cycle again [17].
The presence of Tregs and the decrease in activated T cells play an important 
role in the ability of the cancer to develop. Tregs are immunosuppressive, and in 
the context of the tumor microenvironment, they prevent the host from mounting 
an immune response against the tumor. Interestingly, leptin can both induce and 
prevent differentiation of T cells into Tregs. IFNγ secretion, stimulated by leptin, 
can directly block Treg differentiation. However, the proinflammatory cytokines 
secreted by Th1 T cells, whose differentiation can be induced by leptin, can stimu-
late tumor cells to secrete C-C motif chemokine 22 (CCL22). This chemokine 
recruits Tregs to the TME [17, 42, 43]. It is important to note that while Tregs act to 
suppress the immune system in most cancers, there are some exceptions. Tregs can 
help slow tumor growth in colorectal cancers, as the Tregs can act to decrease the 
inflammation needed by the cancer to grow. However, this effect is likely caused by 
the gut microbiota [44].
The TME can also control adipose-derived stem cell (ASC) activity and fate 
in order to support cancer growth. ASCs are multipotent stem cells in the adipose 
tissue. In the context of the TME, ASCs can be induced to secrete matrix metal-
loproteinases (MMPs). MMPs degrade the extracellular matrix and allow cancer 
cells access to blood vessels to metastasize to other parts of the body. ASCs can also 
induce Treg differentiation in a similar manner as TAMs: via TGFβ and IL-10 secre-
tion. Alternatively, the TME can induce ASC differentiation into cancer-associated 
fibroblast (CAFs) [17], which can then secrete chemokines and growth factors that 
activate pathways related to cell growth and survival [45].
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The TME can also induce hypoxia via anaerobic respiration, even in the presence 
of oxygen [46]. Under hypoxic conditions, ASCs are recruited to the tissue and are 
stimulated to secrete VEGF. This allows formation of blood vessels and angiogen-
esis [17]. Adipocytes can also contribute to angiogenesis in the TME. Adipocytes 
in obese patients have a higher expression of HIF-1α, which is largely because the 
adipocytes are rapidly expanding and proliferating in response to nutrient excess. 
This HIF-1α simulates VEGF secretion. Hypoxia in the adipose tissue also induces 
IL-6 secretion, which can promote insulin secretion [46].
HIF-1α is a transcription factor that activates hypoxia response elements. In 
normal conditions, it is hydrolyzed by prolyl hydroxylase domain proteins (PHDs) 
and ubiquitinated by Von Hippel-Lindau (VHL), which prevents the transcription 
factor from activating its targets. In hypoxia, however, PHDs and VHL are inhib-
ited. HIF-1α can then bind and activate genes that induce macrophage infiltration 
and inflammation [46].
HIF-1α can also regulate expression of glycolytic enzymes. This effect is espe-
cially important during the metabolic reprogramming that occurs as a result of the 
Warburg Effect. Most notably, lactate dehydrogenase alpha (LDHα) is transacti-
vated exclusively by HIF-1α. LDHα is responsible for converting pyruvate to lactate 
during glycolysis in cancer cells [46].
In addition to activating glycolytic pathways, HIF-1α can also block 
OXPHOS. One of the genes that HIF-1α activates is miR-210, a type of miRNA that 
is overexpressed in hypoxia in many cancer cells. miRNAs are small stretches of 
RNA that can bind an inhibit expression of target genes. As such, miR-210 is used as 
a biomarker for tumor hypoxia and is generally correlated with a worse prognosis. 
miRNAs bind mRNA to block their transcription, and miR-201 binds mRNAs that 
are needed for mitochondrial activity. miR-210 can also stabilize HIF-1α, which 
allows the transcription factor to bind and activate hypoxia-inducing genes. In this 
way, miR-210 can also contribute to increase hypoxia [46].
7. Conclusion
Obesity can contribute to cancer progression through a variety of mechanisms. 
However, the main effects of obesity in the context of cancer are activation of path-
ways that lead to drug resistance, inflammation, and dysregulation of sex hormones 
and adipokines. The adipokine leptin plays a central role in the contribution of 
obesity to cancer progression, as it is over-expressed in obesity and contributes to 
insulin secretion and inflammation. Estrogen, IGF-1, and inflammatory factors also 
play pivotal roles cancer progression in the context obesity. However, the mecha-
nisms discussed in this chapter are by no means an exhaustive list of what is known, 
and more research must still be done to completely understand the interplay 
between adipose tissue and the tumor microenvironment.
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